InSphero AG

Company founded: March 2009

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 7 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow.
InSphero's microtissues have shown to be more accurate in predicting compound efficacy and drug-induced toxicology by customers around the world. Most recently, the US/UK-based company Cyprotex, a global leader in toxicology testing, has signed a strategic deal with InSphero to offer commercial screening services based on InSphero's 3D microtissues.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich and was recognized for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.

Milestones / News

Funding Activity 08.07.2015

TOP 100 Startup Award winner InSphero secures CHF 20 million series C financing

Milestone 24.04.2014

InSphero publishes 3D tumor-stroma model for non-small cell lung cancer

Deal 04.04.2014

InSphero to distribute Dainippon Screen imager for rapid profiling of 3D microtissues

Deal 20.03.2014

InSphero announces collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

Milestone 27.02.2014

JBS publication demonstrates utility of InSphero 3D co-culture microtissues as phenotypic RNAi screening tool

Milestone 27.02.2014

InSphero granted hanging drop patents in China and Japan

Milestone 28.01.2014

InSphero hires director of global marketing

Milestone 25.11.2013

InSphero German subsidiary opens for business

Funding Activity 31.05.2013

InSphero secures CHF 2 Million Financing

Deal 24.05.2013

InSphero partners with Roche and others to further develop its 3D microtissue technology in a European grant project HeCaTos

Milestone 16.04.2013

InSphero featured in the world's most highly cited science journal Nature

Milestone 15.04.2013

InSphero opens first office in US and appoints new director

Deal 25.03.2013

Pfizer and InSphero publish significant research results to study drug toxicity

Milestone 29.01.2013

Patent on InSphero’s core technology granted

Milestone 31.12.2012

InSphero moving to new headquarters and expanding production

Milestone 22.11.2012

InSphero's 3D models described in renowned peer-reviewed journal Archives of Toxicology

Milestone 30.10.2012

InSphero ranked number 2 startup of Switzerland

Deal 06.09.2012

Cyprotex Ltd. signs strategic deal to use InSphero microtissues

Deal 28.08.2012

InSphero closes strategic marketing partnerships with Perkin Elmer, Promega and Integra

Deal 24.07.2012

InSphero receives grants from CTI and EU to develop new 3D microtissues with its partners (incl. AstraZeneca and others)

Milestone 17.01.2012

InSphero receives ISO 9001 certification to facilitate its business with big pharma

Deal 31.12.2011

InSphero triples its turnover in 2011

Deal 19.09.2011

Global top-10 cosmetics company closes exclusive supply deal with InSphero

Funding Activity 30.08.2010

1.8 MILLIONEN FRANKEN FÜR INSPHERO

Documents

Videos and Presentations

120 sec introduction to cancer applications of InSphero's 3D InSight™ Tumor Microtissues

>

90 sec introduction to InSphero's 3D InSight™ Liver Microtissues

>

InSphero at IFJ

>

InSphero company video

>

Contact

Sharing

PARTNERS